Although much attention has focused on the opioid epidemic, a parallel methamphetamine crisis rages on while the COVID-19 pandemic continues compounding health care problems across the United States and beyond. With no approved treatments, such as is the case for opioids, a new study, known as ADAPT-2, sponsored by the University of Texas Southwestern Medical Center, points to the potential for a combination of two drugs approved by the U.S. Food and Drug Administration (FDA): one approved for depression and the other for opioid addiction. Of the population under study, 13.6% revealed meth free urine in tests as compared to only 2.5% of those given a placebo. Meth addiction ravages human health and these study results should be at least reviewed by physicians and addiction health professionals.
Meth in America: a Crisis
Approved and regulated Schedule II of the Controlled Substances Act, the drug is approved for pharmacological use in the treatment of attention deficit hyperactivity disorder and treatment-resistant obesity, but it's primarily abused as a recreational, illicit drug. As many as 440,000 people per month are using the drug illicitly. The drug is controlled in so...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).